News und Analysen
The 2 Likely Reasons Novavax Inc. Rocketed Higher by 25% in November
Shares of Novavax (NASDAQ: NVAX), a clinical-stage small-cap biotech company focused on the development of recombinant nanoparticle vaccines, surged by 25% during the month of November, according....
2 Reasons Geron Corporation Took a Pounding in November
Shares of Geron Corporation (NASDAQ: GERN), a clinical-stage biotech company focused on the development of oncology drugs, sank 12% during the month of November, according to data from S&P....
The Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in November
Shares of Valeant Pharmaceuticals (NYSE: VRX), an embattled drugmaker that had primarily grown by acquisitions and drug-price hikes in recent years, galloped higher by 43% in November, according....
5 Key Things to Know About This Leading Marijuana Stock's Future
You can count the number of pure-play marijuana stocks with a market cap of around $3 billion on one hand -- and have several fingers left over. GW Pharmaceuticals (NASDAQ: GWPH) ranks as one of....
Veeva Systems Inc. (VEEV) Q3 2018 Earnings Conference Call Transcript
Image source: The Motley Fool.Veeva Systems Inc. (NYSE: VEEV)Q3 2018 Earnings Conference CallDec. 5, 2017, 4:30 p.m. ETOperatorContinue readingSource: Fool.com
3 Growth Stocks With Virtual Monopolies
Monopolies can be bad. Having a single company control every aspect of an entire industry is likely to lead to higher consumer prices, slower innovation, and anticompetitive behavior.Lucky for us,....
Why Heron Therapeutics Stock Is Crashing Today
Heron Therapeutics (NASDAQ: HRTX), a commercial-stage biotech developing medicines to address unmet medical needs, saw its shares drop by as much as 11.8% today on over five times the average....
Why Snap, Regal Entertainment Group, and Revance Therapeutics Jumped Today
Tuesday was a down day for most of the stock market, with major benchmarks finishing with modest losses of half a percent or less. The NYSE Composite pulled back from the record highs it reached....
Why Illumina Jumped 9.8% in November
Shares of the genomic sequencing specialist Illumina (NASDAQ: ILMN) rose nearly 10% in November, according to data from S&P Global Market Intelligence. However, there wasn't any....
Why Alexion Pharmacteuicals Sank 8.9% in November
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a commercial-stage biotech focused on rare diseases, fell 9% in November, according to data from S&P Global Market Intelligence. There doesn't....
MEDICREA : Declaration_des_droits_de_vote_AMF_30-11-2017
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL
(Article L.233-8-II du Code de Commerce et Article 222-12-5 du règlement général de....
VISIOMED GROUP lève 2,6 MEUR pour poursuivre son développement dans la santé connectée
Paris, le 5 décembre 2017
VISIOMED GROUP (FR0011067669 – ALVMG), société spécialisée dans l'électronique médicale nouvelle génération, annonce la réalisation d'une augmentation de 2,6 M€ qui....
Here's Why Collegium Pharmaceutical Rose as Much as 23.5% Today
Shares of specialty pharmaceutical developer Collegium Pharmaceutical (NASDAQ: COLL) rose over 23% today after the company announced that it will acquire the pain drug Nucynta from Depomed....
Why Revance Therapeutics Is Soaring Today
In response to the company's strong results from two pivotal phase 3 trials, shares of Revance Therapeutics (NASDAQ: RVNC), a clinical-stage biotech focused on aesthetics, rose 36% as of 11:10....
MorphoSys: Partner erhält Medikamenten-Zulassung in Kanada
Der MorphoSys-Lizenzpartner Janssen hat in Kanada die Zulassung zur Behandlung erwachsener Patienten mit moderater bis schwerer Form von Schuppenflechte mit dem Medikament Tremfya erhalten. Das....
Why Nektar Therapeutics Shares Delivered a Stupendous 124% in November
After the company updated the timeline for filing its pain-relieving drug for approval from the Food and Drug Administration, and presented early-stage study results for its solid-tumor cancer....
3 Things Veeva Systems Inc. Shareholders Should Watch Going Into Earnings
Veeva Systems (NYSE: VEEV), which provides cloud solutions primarily to pharmaceutical companies, will be reporting earnings next week. While the stock has been a resounding success over the past....
What Happened in the Stock Market Today
Stocks began the day in positive territory thanks to optimism over the Senate's passage of a tax bill, but declined over the length of the session, ultimately ending with mixed results. The Dow....
Why Ra Pharmaceuticals, Inc. Got Hammered Today
Ra Pharmaceuticals (NASDAQ: RARX) characterized its interim phase 2 data testing RA101495 SC in patients with paroxysmal nocturnal hemoglobinuria (PNH) as "positive," but the market sees it....
Why Endocyte, Inc. Stock Briefly Spiked Today
Shares of the clinical-stage biotech Endocyte (NASDAQ: ECYT) briefly rose by as much as 16% Monday on more than double the average daily volume. The catalyst? Investors appear to have noticed a....
1 High-Risk Penny Stock That May Be Worth Buying
Penny stocks, or stocks with a sub-$5 share price, generally aren't my cup of tea. These types of companies tend to be far too risky to make them worthy of serious investment consideration. The....
BASTIDE : Déclaration du nombre d'actions et de droits de vote au 30.11.2017
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12 avenue de la Dame, Zone Euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
DROITS DE....
3 Stocks That Quadrupled
The stock market continues to put on a clinic about how to stomp all over expectations. The Dow Jones Industrial Average is up 25% this year and the S&P 500 is 20% higher, but stack them up....
Where Will Exact Sciences Corporation Be in 5 Years?
Roughly 18 months ago, Exact Sciences (NASDAQ: EXAS) was in rough shape. Cash was getting tight as the company spent aggressively to commercialize its new colon cancer test. Add in some troubling....
3 Reasons Pfizer Should Buy Celgene in 2018
You might think it's a crazy idea. Maybe it is a crazy idea. But sometimes crazy ideas are the ones that wind up being the best. So here it is: Pfizer (NYSE: PFE) should buy Celgene (NASDAQ: CELG)....